Conference Reports for NATAP

Back

IAS 2019: Conference on HIV Pathogenesis Treatment and Prevention Mexico City July 21-24 2019     Hormonal control of HIV-1 latency by estrogen imparts gender-specific restrictions on the latent reservoir - (09/03/19)   Symptom Burden and Inflammatory Cytokines in PLWH in the US: an analysis by sex, menopause stage and menstrual cycle phase - (09/03/19)   Smoking and High HIV Viremia Damage Mitochondrial DNA and May Accelerate mtDNA Aging - (09/03/19)   10th International AIDS Society Conference on HIV Science - (09/03/19)   TDF/FTC Pre-Exposure Prophylaxis (PrEP) from 2012 to 2018 in the OPERA Cohort - (08/16/19)   Cost-effectiveness of Dolutegravir in HIV-1 Treatment-Naive Patients in Mexico - (08/16/19)   Changing Rates of Heavily Treatment Experienced Persons with HIV in the United States, 2000-2017 - (08/16/19)   Is DTG+3TC and DTG+RPV Effective and Safe in Clinical Practice? Evidence From Real World Data - (08/16/19)   High HIV incidence among young women in South Africa: data from the ECHO trial - (08/13/19)   Shorter CD8 T Cell Subset Telomeres and Lower Proliferative:Senescent CD8 Ratio in People with Chronic/Latent Viral Coinfections - (08/13/19)   PrEP use in young African women in HPTN 082: Effect of drug level feedback - (08/13/19)   HIV Prevention at IAS 2019 10th IAS Conference on HIV Science, Mexico City, Mexico 21-24 July 2019 - Jared Baeten, MD PhD Connie Celum, MD MPH University of Washington (08/12/19)   Substance Use--Especially Meth--Tied to Depression in Young HIV+/HIV- MSM - Mark Mascolini (08/06/19)   "Dual epidemics: the impact of HIV and obesity on pregnancy outcomes among women in South Africa" 'The impact of HIV and obesity on pregnancy outcomes among women in South Africa' Obesity in 36% of Pregnant HIV+ South African Women--But No Impact on Outcomes - (08/05/19)   Adverse pregnancy outcomes among HIV-positive women in the era of universal antiretroviral therapy (ART) remain elevated compared with HIV-negative women in Lesotho - (08/05/19)   Higher Immune Activation With Methadone Than Naltrexone in Opioid Users With HIV - Mark Mascolini (08/05/19)   Inflammatory Marker and Immune Upsets After Single Forced Vaginal Penetration - Mark Mascolini (08/05/19)   DMPA May Have STI Advantage Over Copper IUD and Levonorgestrel Implant - Mark Mascolini (08/05/19)   Comorbidities Canadians: >70 HIGH Rates - (08/05/19)   Perspectives from the Front Lines: Encouraging Community Engagement in the Performance of Research at the Intersection of HIV and Aging - (08/05/19)   A SWITCH TO DOLUTEGRAVIR IN COMBINATION WITH BOOSTED DARUNAVIR IS SAFE AND EFFECTIVE IN SUPPRESSED PATIENTS WITH HIV - A SUBANALYSIS OF THE DUALIS STUDY - (08/02/19)   Five Times Higher Risk of ART Nonadherence on Days of Heavy Drinking - Mark Mascolini (08/02/19)   Dolutegravir use at conception: Additional surveillance data from Botswana (smaller signal) - (08/02/19)   No occurrences of neural tube defects among 382 women on Dolutegravir at pregnancy conception in Brazil - (08/02/19)   Neural-Tube Defects and Antiretroviral Treatment Regimens in Botswana - (08/02/19)   A SWITCH TO DOLUTEGRAVIR IN COMBINATION WITH BOOSTED DARUNAVIR IS SAFE AND EFFECTIVE IN SUPPRESSED PATIENTS WITH HIV - A SUBANALYSIS OF THE DUALIS STUDY - (08/01/19)   HCV Reinfection Rate in People With HCV/HIV 13% Across Europe - Mark Mascolini - (08/01/19)   Inconsistent Testing in HIV+ for Top Liver Cancer Risk Factors: HBV, HCV, Alcohol - Mark Mascolini (08/01/19)   Biomarkers Good at Predicting NAFLD or Excluding Advanced Fibrosis With HIV (FibroScan, CAP Score) - Mark Mascolini (08/01/19)   Virologic Failure In ART-Naive HIV Patients With High Pre-Therapy Viral Load Burden Initiating On Common Core Agents - (08/01/19)   Biomarkers Good at Predicting NAFLD or Excluding Advanced Fibrosis With HIV (FibroScan, CAP Score) - Mark Mascolini (07/31/19)   Collaborative Care Improves HIV Provider Confidence in Managing Chronic Opioid Therapy - Mark Mascolini (07/31/19)   Preventive HIV vaccine Enters Phase 3 Global Study - (07/30/19)   More Acute HIV Diagnoses, Shorter Time to Undetectable HIV, in Amsterdam MSM Program - Mark Mascolini (07/30/19)   Substance Use--Especially Meth--Tied to Depression in Young HIV+/HIV- MSM - Mark Mascolini (07/30/19)   HIV Control Rate Lower in Women Than Men in Inner-City Vancouver - Mark Mascolini (07/30/19)   Meta-Analysis Confirms Aerobic Exercise Benefit on Depression With HIV - Mark Mascolini (07/30/19)   Week 96 Resistance and Adherence Analyses of the Once-daily, Single-tablet Regimen Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) in the AMBER and EMERALD Phase III Trials - (07/30/19)   Change in Kidney Function After TDF-to-TAF Switch: Who Benefits Most? - Mark Mascolini (07/30/19)   In Vitro Resistance Profile of GS-6207, a First-in-Class Picomolar HIV Capsid Inhibitor in Clinical Development as a Novel Long-Acting Antiretroviral Agent - (07/30/19)   Johnson & Johnson Announces New Clinical Data on Mosaic-based HIV Preventive Vaccine Regimen - (07/30/19)   Johnson & Johnson Announces New Public-Private Partnership to Support First Phase 3 Efficacy Study of Janssen's Investigational Prophylactic HIV Vaccine - (07/30/19)   Long-Acting MK-8591 at IAS 2019, , New ART for Treatment, PrEP - (07/30/19)   Prevalence and Outcomes for Heavily Treatment-Experienced (HTE) Individuals Living with HIV in a European Cohort EuroSIDA - (07/28/19)   WHO recommends dolutegravir as preferred HIV treatment option in all populations - (07/28/19)   HPTN 078: Primary results of a randomized study to engage men who have sex with men (MSM) living with HIV who are virally unsuppressed in the USA - (07/28/19)   ViiV Healthcare submits regulatory application to European Medicines Agency for investigational cabotegravir to be used in combination with rilpivirine as the first monthly, injectable treatment for HIV - (07/28/19)   Efficacy of on-demand PrEP or PEP with single oral doses of combination tenofovir alafenamide, emtricitabine, elvitegravir, and cobicistat in macaques - (07/28/19)   Polypharmacy in Nearly All of 65+ HIV Group Tied to Inappropriate Prescribing - (07/28/19)   Loneliness Among Older People (44%) Living with HIV: Why the ''Older Old'' are Less Lonely Than the ''Younger Old'' (53%) - (07/28/19)   "There's no retirement plans for us": Re-analysis from a qualitative study of HIV-positive MSM who use substances - (07/27/19)   The ADVANCE trial: Phase 3, randomized comparison of TAF/FTC/DTG, TDF/FTC/DTG or TDF/FTC/EFV for first-line treatment of HIV-1 infection - (07/27/19)   Dolutegravir (DTG) Plus Lamivudine (3TC) Versus DTG Plus Tenofovir/Emtricitabine (TDF/FTC) Fixed-Dose Combination in the GEMINI Studies -Viral Load Rebound Including 'Blips' Through 48 Weeks - (07/27/19)   ARTS 4 Days A Week Instead of 7, not good, Jules. - "ANRS 170 QUATUOR 4/7 days maintenance strategy in antiretroviral treated adults with HIV-1 infection: an open randomised parallel non-inferiority phase III trial" - (07/27/19)   Twice-Daily 400-mg Raltegravir Not Noninferior to Efavirenz for HIV With TB - "Virologic efficacy of raltegravir vs. efavirenz-based antiretroviral treatment in HIV1-infected adults with tuberculosis: W48 results of the ANRS 12300 REFLATE TB2 trial" - (07/27/19)   Rosuvastatin Does Not Slow Atherosclerosis in HIV+ With Moderate Risk - (07/27/19)   SWITCHING TO DTG/3TC FIXED-DOSE COMBINATION (FDC) IS NON-INFERIOR TO CONTINUING A TAF-BASED REGIMEN IN MAINTAINING VIROLOGIC SUPPRESSION THROUGH 48 WEEKS (TANGO STUDY) - (07/26/19)   Out-of-Care HIV+ US MSM Will Resume Treatment, But Only Half Control HIV in 12 Months - Mark Mascolini - (07/26/19)   A Pooled Analysis of the Effect of Adherence on the Renal Safety of FTC/TDF (Truvada) for Prep: 7 International Demonstration Projects - (07/26/19)   ViiV Healthcare presents GEMINI 1 & 2 studies through Week 96 showing 2-drug regimen of dolutegravir plus lamivudine continues to demonstrate high efficacy rates and no cases of treatment emergent resistance - PRESS RELEASE - (07/26/19)   Merck Announces Presentation of Phase 2b Results for Investigational HIV-1 Therapy Islatravir (MK-8591) at IAS 2019 - (07/26/19)   ViiV Healthcare announces positive Week 48 results in first study to evaluate treatment switch from TAF-containing regimen with three or more drugs to 2-drug regimen of dolutegravir/lamivudine for HIV-1 infection - PRESS RELEASE - (07/26/19)   Vesatolimod (GS-9620) Is Safe and Pharmacodynamically Active in HIV-Infected Individuals - (07/26/19)   ISLATRAVIR (ISL, MK-8591) at doses of 0.25 to 2.25 mg QD in combination with doravirine maintains viral suppression through 48 weeks in adults with HIV-1 infection - (07/26/19)   Gilead Announces Latest Data in Ongoing HIV Cure Research Program - (07/25/19)   Gilead Presents New Findings on Profile of Descovy for Potential Use as HIV Pre-exposure Prophylaxis Compared With Truvada - (07/25/19)   Gilead Presents Proof-of-Concept Data for GS-6207, a First-in-Class Capsid Inhibitor, in People Living With HIV - (07/25/19)   Incidence of HIV-Infection with Daily or On Demand PrEP with TDF/FTC in the Paris Area: An Update of the Prevenir Study - (07/25/19)   Progressive rises in weight and clinical obesity for TAF/FTC+DTG and TDF/FTC+DTG versus TDF/FTC/EFV: ADVANCE and NAMSAL trials - (07/25/19)   Oral TLR7 Agonist Administration Induces an Immunostimulatory Response in SIV-Infected ART-Suppressed Infant Rhesus Macaques - (07/25/19)   Out-of-Care HIV+ US MSM Will Resume Treatment, But Only Half Control HIV in 12 Months - Mark Mascolini - (07/25/19)   Vision Impairment More Frequent in Older HIV+ Men--With Functional Consequences - Mark Mascolini - (07/25/19)   Lower HIV Rate With F/TAF Than F/TDF in Double-Blind Noninferiority Trial - Mark Mascolini - (07/25/19)   Neural Tube Defect Rate 0.40% With Dolutegravir in Pregnancy--But Data Still Slim - Mark Mascolini - (07/25/19)   High STI Prevalence in German MSM, But Low Rates of HIV, HCV, HBV - Mark Mascolini - (07/25/19)   About 10% With HIV in Europe Have Heavy Treatment Experience, Few Options - "Prevalence and outcomes for heavily treatment-experienced (HTE) individuals living with HIV in a European cohort" - Mark Mascolini - (07/25/19)   Almost No New HIV Infections in Paris Comparison of Daily vs As-Needed PrEP - Mark Mascolini - (07/25/19)   Higher GI Disorder Risk When Switching to RAL or DRV Versus DTG - Mark Mascolini - (07/25/19)   Young Men Driving Expanding HIV Epidemic in Latin America - Mark Mascolini - (07/25/19)   Better Predictive Power When Combining Traditional and HIV-Specific Cardio Risk Factors - "Impact of HIV specific and traditional risk factors on the incidence of cardiovascular events in HIV-positive males over time" - Mark Mascolini - (07/25/19)   Viral Suppression in 60% for 96 Weeks With Fostemsavir Salvage in BRIGHTE - Mark Mascolini - (07/25/19)   Week-96 Potency of Dolutegravir/3TC in GEMINI Trials of First-Line ART - "Durable efficacy of dolutegravir (DTG) plus lamivudine (3TC) in antiretroviral treatment-naive adults with HIV-1 infection--96-week results from the GEMINI studies" - Mark Mascolini - (07/25/19)   Sharp Drops in HIV Load After 10 Days of Capsid Inhibitor Monotherapy - Mark Mascolini - (07/25/19)   Simulated Driving Worse in Pro Drivers With Than Without HIV - "Cognitive functioning and driving ability in HIV-infected professional drivers" - Mark Mascolini - (07/25/19)   HIV Infection Rate Jumps 7.5-fold When US PrEP Users Stop - Mark Mascolini - (07/25/19)   Differential Detection of M184V/I Between Plasma Historical HIV Genotypes and Proviral DNA from PBMCs - (07/25/19)   Switching to a Single-tablet Regimen of Bictegravir, Emtricitabine, and Tenofovir Alafenamide (B/F/TAF) from Dolutegravir plus Either F/TAF or F/TDF - (07/25/19)   A Subgroup Analysis of the Week 96 Efficacy and Safety Results Evaluating Fostemsavir in Heavily Treatment-Experienced HIV-1 Infected Participants in the Phase 3 BRIGHTE Study: Results From The Randomized Cohort - (07/25/19)   First-in-Human Trial of MK-8591-Eluting Implants Demonstrates Concentrations Suitable for HIV Prophylaxis for at Least One Year - (07/25/19)   Keeping the Pressure on Archived NRTI Resistance: Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) Triple Therapy in Study 4030 - (07/25/19)   Week 96 safety and efficacy of the novel HIV-1 attachment inhibitor prodrug fostemsavir in heavily treatment-experienced participants infected with multi-drug-resistant HIV-1 (BRIGHTE Study) - (07/25/19)   Previously Undocumented Pre-existing Resistance and Maintenance of Virologic Suppression in HIV-1 RNA-Suppressed Patients Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) - (07/25/19)   Tolerability, Safety, and Efficacy of Islatravir (MK-8591) at Doses of 0.25 to 2.25 mg QD, in Combination With Doravirine and Lamivudine Through 24 Weeks in Treatment-Naïve AdultsWith HIV-1 Infection - (07/25/19)   Longer-term (96-week) Efficacy and Safety of Switching to Bictegravir, Emtricitabine and Tenofovir Alafenamide (B/F/TAF) in Women - (07/25/19)   Utilization of Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) for HIV Pre-Exposure Prophylaxis (PrEP) in the United States by Age, Gender and Race/Ethnicity (2014 - 2017) - (07/25/19)   Long-Acting Cabotegravir and Rilpivirine is Noninferior to Oral ART as Maintenance Therapy for HIV-1 Infection: Week 48 Pooled Analysis From the Phase 3 ATLAS and FLAIR Studies - (07/25/19)   Patient-Reported Outcomes on Long-Acting Cabotegravir + Rilpivirine as Maintenance Therapy: FLAIR 48-Week Results - (07/25/19)   Patient Views on Long-Acting HIV Treatment: Cabotegravir + Rilpivirine as Maintenance Therapy (ATLAS 48-Week Results) - (07/25/19)   DISCOVER STUDY for HIV Pre-Exposure Prophylaxis: F/TAF has a more Rapid Onset and Longer Sustained Duration of HIV Protection Compared with F/TDF - (07/25/19)   Forgiveness of Antiretroviral Regimens: In Vitro HIV-1 Viral Breakthrough with 2-Drug versus 3-Drug Regimens Simulating Variable Adherence to Treatment - (07/23/19)   Viral Suppression in 60% for 96 Weeks With Fostemsavir Salvage in BRIGHTE - Mark Mascolini - (07/23/19)   ViiV Healthcare announces positive phase 3 results from the BRIGHTE study of fostemsavir in heavily treatment-experienced patients with HIV - (07/23/19)   Gilead Presents New Data on Biktarvy for the Treatment of HIV in Women and in Virologically Suppressed Patients With Known Resistance - (07/23/19)   Gilead Presents Proof-of-Concept Data for GS-6207, a First-in-Class Capsid Inhibitor, in People Living With HIV - (07/23/19)   Gilead to Present New Data on HIV Prevention, Treatment and Cure Research at IAS 2019 - (07/18/19)   IAS 2019: ViiV Healthcare showcasing innovation in HIV science - PRESS RELEASE - (07/16/19)   Merck Highlights Commitment to HIV Research with Presentations for Investigational Anti-HIV Agent MK-8591 at IAS 2019 - (07/10/19)